Recommendation for diagnosis and treatment of fabry’s disease in Slovenia
Abstract
Background: Fabry disease is a rare X-chromosome linked disease. Due to gene mutation, activity of enzyme α galactosidase A is lowered or absent and sphingolipids are deposited in different organ cells. All males with gene mutation are affected but females too, due to X chromosome inactivation, can frequently be affected as well, although usually to a lesser extend. Disease is slowly progressive and there is an early dysfunction of several organs, specially endothelium, kidney, heart and central nervous system, which all leads to early death of the patient.
Conclusions: Recently, a specific enzyme replacement therapy, based on recombinant technology, was discovered. Specific therapy is effective and safe. Due to a new therapy there was a need to set objective criteria when to start with enzyme replacement therapy, but also a need to more complex, multidisciplinary approach to those patients. This article is an initial proposal for systematic management of Fabry disease in our country.
Downloads
References
Hughes DA, Ramswami U, Elliott P, Deegan P, Lee P, Waldek S, et al. Guidelines for the diagnosis and management of Anderson-Fabry disease. Dosegljivo na: http://www.dh.gov.uk/PublicationsAndStatistics/Publications/ PublicationsPolicyAndGuidance/ PublicationsPolicyAndGuidanceArticle/fs/en?CONTENT ID=4118404&chk=oSyxOB
Brady RO, Gal AE, Bradley RM, et al. Enzymatic defect in Fabry’s disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276:1163.
Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mutat 1994; 3:103–11.
Eng CM, Ashley GA, Burgert TS, et al. Fabry’s disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3: 174–82.
Topaloglu AK, Ashley GA, Tong B, et al. Twenty novel mutations in the alpha-galactosidase A gene causing Fabry’s disease. Mol Med 1999; 5: 806–11.
Meikle PJ, Hopwood JJ, Clague AE, et al. Prevalence of lysosomal storage disorders. JAMA 1999: 281: 249–54.
Van Loo A, Vanholder R, Madsen K, et al. Novel frameshift mutation in a heterozygous woman with Fabry disease and endstage renal failure. Am J Nephrol 1996; 16: 352–57.
MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestation and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38: 769–75.
Desnick RJ, Brady R, Barranger J, Collins AJ. Fabry’s disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138: 338–46.
Desnick RJ, Sweeley CC. Fabry’s disease: Alpha-galactosidase A deficiency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, eds. Peripheral neuropathy. Vol. 2. New York: McGraw Hill; 1983.
Scott LJ, Griffin JW, Luciano C, et al. Quantitative analysis of epidermal innervation in Fabry’s disease. Neurology 1999; 52: 1249– 54.
Desnick RJ, Brady RO. Fabry disease in childhood. J Pediatr 2004; 144: S20–6.
Sher NA, Letson RD, Desnick RJ. The ocular manifestations in Fabry’s disease. Arch Ophthalmol 1979; 97: 671–6.
Von Scheidt W, Eng CM, Fitzmaurice TF, et al. An atypical variant of Fabry’s disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395–9.
Kampmann C, Baechner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002; 13: S134–8.
Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry’s disease. Neurology 1998; 50: 1746–9.
Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996; 40: 8–17.
Thadhani R, Wolf M, West ML, et al. Patients with Fabry disease on dialysis in the United States and Europe. Kidney Int 2002; 61: 249–55.
Branton MH, Schiffmann R, Sabnis SG, et al. Natural history of Fabry disease: influence of alpha-galactosidase A activity and genetic mutation on clinical course. Medicine 2002; 81: 122–38.
Verovnik F, Vujkovac B, Benko D, Lindhorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet 2004; 12: 678–81.
Desnick RJ, Allen KY, Desnick SJ, et al. Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973: 81: 157.
Meschia JF, Brott TG, Brown RD Jr. Genetics of cerebrovascular disorders. Mayo Clin Proc 2005; 80: 122–32.
Caggana M, Ashley GA, Desnick RJ, Eng CM. Fabry’s disease: molecular carrier detection and prenatal diagnosis by analysis of closely linked polymorphisms at Xq22.1. Am J Med Genet 1997; 71: 329–35.
Whybra C, Kampmann C, Krummenauer F, et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 2004; 65: 299–307.
Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry’s disease. N Engl J Med 2001; 345: 9–16.
Schiffmann R, Kopp JB, Austin HA, et al. Enzyme replacement therapy in Fabry’s disease: a randomized controlled trial. JAMA 2001; 285: 2743–9.
MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38: 750–60.
Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulatio. 2003; 16: 1299–301.
Waldek S. PR interval and the response to enzyme-replacement therapy for Fabry’s disease. N Engl J Med 2003; 20: 1186–7.
Hajioff D, Goodwin S, Quiney R, et al. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr Suppl 2003; 92: 28–30.
Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, A delta-, and A beta-nerve fibers in Fabry neuropathy. Neurology 2004; 13: 1066–72.
Dehout F, Roland D, Treille de Granseigne S, et al. Relief of gastrointestinal symptoms under enzyme replacement therapy in patients with Fabry disease. J Inherit Metab Dis 2004; 27: 499– 505.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
